nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.12.2014

Post-transcriptional regulation of MTA family by microRNAs in the context of cancer

verfasst von: Yun Zhang, Xiao-Fan Wang

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

MicroRNAs (miRNAs) are a class of 20–24 nt small non-coding RNAs that regulate a wide range of biological processes through changing the stability and translation of their target messenger RNA (mRNA) genes. Shortly after their identification, many miRNA genes have been found dysregulated in a variety of human cancers, indicating a pathological function of this gene class in mediating cancer progression. Over the past decade, accumulated literature has shown that miRNAs participate in numerous cancer-relevant processes including cell proliferation, apoptosis, differentiation, metabolism, and importantly, metastasis, which accounts for the mortality of approximately 90 % of cancer patients. Several recent publications have linked miRNAs with metastasis-associated protein (MTA) family members. Given the fact that the MTA family members are widely overexpressed in human cancers and their nature of serving as both corepressor and coactivator in gene regulation, it is intriguing to study whether certain miRNAs regulate cancer progression through modulating the expression of MTA family members. In this review, we will focus on recent advances in understanding the regulatory relationship between certain miRNAs and MTA family members.

Eddy, S. R. (2001). Non-coding RNA genes and the modern RNA world. Nature Reviews Genetics, 2(12), 919–929. doi:10.1038/35103511.PubMedCrossRef

Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116(2), 281–297.PubMedCrossRef

Bushati, N., & Cohen, S. M. (2007). MicroRNA functions. Annual Review of Cell and Developmental Biology, 23, 175–205. doi:10.1146/annurev.cellbio.23.090506.123406.PubMedCrossRef

Calin, G. A., & Croce, C. M. (2006). MicroRNA signatures in human cancers. Nature Reviews Cancer, 6(11), 857–866. doi:10.1038/nrc1997.PubMedCrossRef

Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., et al. (2005). MicroRNA expression profiles classify human cancers. Nature, 435(7043), 834–838. doi:10.1038/nature03702.PubMedCrossRef

Sayed, D., & Abdellatif, M. (2011). MicroRNAs in development and disease. Physiological Reviews, 91(3), 827–887. doi:10.1152/physrev.00006.2010.PubMedCrossRef

Esquela-Kerscher, A., & Slack, F. J. (2006). Oncomirs—microRNAs with a role in cancer. Nature Reviews Cancer, 6(4), 259–269. doi:10.1038/nrc1840.PubMedCrossRef

Hammond, S. M. (2007). MicroRNAs as tumor suppressors. Nature Genetics, 39(5), 582–583.PubMedCrossRef

Chen, C. Z. (2005). MicroRNAs as oncogenes and tumor suppressors. New England Journal of Medicine, 353(17), 1768–1771. doi:10.1056/Nejmp058190.PubMedCrossRef

10.

Nicoloso, M. S., Spizzo, R., Shimizu, M., Rossi, S., & Calin, G. A. (2009). MicroRNAs—the micro steering wheel of tumour metastases. Nature Reviews Cancer, 9(4), 293–302. doi:10.1038/nrc2619.PubMedCrossRef

11.

Ma, L., & Weinberg, R. A. (2008). Micromanagers of malignancy: role of microRNAs in regulating metastasis. Trends in Genetics, 24(9), 448–456. doi:10.1016/j.tig.2008.06.004.PubMedCrossRef

12.

Kim, V. N. (2005). MicroRNA biogenesis: coordinated cropping and dicing. Nature Reviews Molecular Cell Biology, 6(5), 376–385. doi:10.1038/nrm1644.PubMedCrossRef

13.

Bartel, D. P. (2009). MicroRNAs: target recognition and regulatory functions. Cell, 136(2), 215–233. doi:10.1016/j.cell.2009.01.002.PubMedCentralPubMedCrossRef

14.

Fabian, M. R., & Sonenberg, N. (2012). The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nature Structural and Molecular Biology, 19(6), 586–593. doi:10.1038/nsmb.2296.PubMedCrossRef

15.

Ameres, S. L., & Zamore, P. D. (2013). Diversifying microRNA sequence and function. Nature Reviews Molecular Cell Biology, 14(8), 475–488. doi:10.1038/nrm3611.PubMedCrossRef

16.

Calin, G. A., Sevignani, C., Dan Dumitru, C., Hyslop, T., Noch, E., Yendamuri, S., et al. (2004). Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proceedings of the National Academy of Sciences of the United States of America, 101(9), 2999–3004. doi:10.1073/Pnas.0307323101.PubMedCentralPubMedCrossRef

17.

Gaur, A., Jewell, D. A., Liang, Y., Ridzon, D., Moore, J. H., Chen, C. F., et al. (2007). Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Research, 67(6), 2456–2468. doi:10.1158/0008-5472.Can-06-2698.PubMedCrossRef

18.

Connolly, E., Melegari, M., Landgraf, P., Tchaikovskaya, T., Tennant, B. C., Slagle, B. L., et al. (2008). Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. American Journal of Pathology, 173(3), 856–864. doi:10.2353/ajpath.2008.080096.PubMedCentralPubMedCrossRef

19.

Diosdado, B., van de Wiel, M. A., Terhaar Sive Droste, J. S., Mongera, S., Postma, C., Meijerink, W. J., et al. (2009). MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression. British Journal of Cancer, 101(4), 707–714. doi:10.1038/sj.bjc.6605037.PubMedCentralPubMedCrossRef

20.

Inomata, M., Tagawa, H., Guo, Y. M., Kameoka, Y., Takahashi, N., & Sawada, K. (2009). MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood, 113(2), 396–402. doi:10.1182/blood-2008-07-163907.PubMedCrossRef

21.

Mavrakis, K. J., Wolfe, A. L., Oricchio, E., Palomero, T., de Keersmaecker, K., McJunkin, K., et al. (2010). Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nature Cell Biology, 12(4), 372–379. doi:10.1038/ncb2037.PubMedCentralPubMedCrossRef

22.

Huang, G., Nishimoto, K., Zhou, Z., Hughes, D., & Kleinerman, E. S. (2012). miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Research, 72(4), 908–916. doi:10.1158/0008-5472.CAN-11-1460.PubMedCentralPubMedCrossRef

23.

Kim, K., Chadalapaka, G., Lee, S. O., Yamada, D., Sastre-Garau, X., Defossez, P. A., et al. (2012). Identification of oncogenic microRNA-17-92/ZBTB4/specificity protein axis in breast cancer. Oncogene, 31(8), 1034–1044. doi:10.1038/onc.2011.296.PubMedCentralPubMedCrossRef

24.

He, L., Thomson, J. M., Hemann, M. T., Hernando-Monge, E., Mu, D., Goodson, S., et al. (2005). A microRNA polycistron as a potential human oncogene. Nature, 435(7043), 828–833. doi:10.1038/Nature03552.PubMedCrossRef

25.

Dews, M., Homayouni, A., Yu, D., Murphy, D., Sevignani, C., Wentzel, E., et al. (2006). Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nature Genetics, 38(9), 1060–1065. doi:10.1038/ng1855.PubMedCentralPubMedCrossRef

26.

Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., et al. (2005). RAS is regulated by the let-7 microRNA family. Cell, 120(5), 635–647. doi:10.1016/J.Cell.2005.01.014.PubMedCrossRef

27.

Chang, T. C., Yu, D., Lee, Y. S., Wentzel, E. A., Arking, D. E., West, K. M., et al. (2008). Widespread microRNA repression by Myc contributes to tumorigenesis. Nature Genetics, 40(1), 43–50. doi:10.1038/ng.2007.30.PubMedCentralPubMedCrossRef

28.

Ma, L., Teruya-Feldstein, J., & Weinberg, R. A. (2007). Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature, 449(7163), 682–688. doi:10.1038/nature06174.PubMedCrossRef

29.

Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., et al. (2008). The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nature Cell Biology, 10(5), 593–601. doi:10.1038/ncb1722.PubMedCrossRef

30.

Tavazoie, S. F., Alarcon, C., Oskarsson, T., Padua, D., Wang, Q. Q., Bos, P. D., et al. (2008). Endogenous human microRNAs that suppress breast cancer metastasis. Nature, 451(7175), 147–152. doi:10.1038/Nature06487.PubMedCentralPubMedCrossRef

31.

Zhang, Y., Yang, P., & Wang, X. F. (2014). Microenvironmental regulation of cancer metastasis by miRNAs. Trends in Cell Biology, 24(3), 153–160. doi:10.1016/j.tcb.2013.09.007.PubMedCrossRef

32.

Manavathi, B., & Kumar, R. (2007). Metastasis tumor antigens, an emerging family of multifaceted master coregulators. Journal of Biological Chemistry, 282(3), 1529–1533. doi:10.1074/jbc.R600029200.PubMedCrossRef

33.

Toh, Y., & Nicolson, G. L. (2009). The role of the MTA family and their encoded proteins in human cancers: Molecular functions and clinical implications. Clinical & Experimental Metastasis, 26(3), 215–227. doi:10.1007/s10585-008-9233-8.CrossRef

34.

Toh, Y., Pencil, S. D., & Nicolson, G. L. (1994). A novel candidate metastasis-associated gene, MTA1, differentially expressed in highly metastatic mammary adenocarcinoma cell-lines—cDNA cloning, expression, and protein analyses. Journal of Biological Chemistry, 269(37), 22958–22963.PubMed

35.

Xue, Y. T., Wong, J. M., Moreno, G. T., Young, M. K., Cote, J., & Wang, W. D. (1998). NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities. Molecular Cell, 2(6), 851–861. doi:10.1016/s1097-2765(00)80299-3.PubMedCrossRef

36.

Ng, H. H., & Bird, A. (2000). Histone deacetylases: silencers for hire. Trends in Biochemical Sciences, 25(3), 121–126.PubMedCrossRef

37.

Denslow, S. A., & Wade, P. A. (2007). The human Mi-2/NuRD complex and gene regulation. Oncogene, 26(37), 5433–5438. doi:10.1038/sj.onc.1210611.PubMedCrossRef

38.

Bowen, N. J., Fujita, N., Kajita, M., & Wade, P. A. (2004). Mi-2/NuRD: multiple complexes for many purposes. Biochimica Et Biophysica Acta - Gene Structure and Expression, 1677(1–3), 52–57. doi:10.1016/j.bbaexp.2003.10.010.CrossRef

39.

Li, D. Q., Pakala, S. B., Nair, S. S., Eswaran, J., & Kumar, R. (2012). Metastasis-associated protein 1/nucleosome remodeling and histone deacetylase complex in cancer. Cancer Research, 72(2), 387–394. doi:10.1158/0008-5472.CAN-11-2345.PubMedCentralPubMedCrossRef

40.

Fujita, N., Jaye, D. L., Kajita, M., Geigerman, C., Moreno, C. S., & Wade, P. A. (2003). MTA3, a Mi-2/NuRD complex subunit, an invasive growth pathway in breast. Cell, 113(2), 207–219. doi:10.1016/s0092-8674(03)00234-4.PubMedCrossRef

41.

Ohshiro, K., Rayala, S. K., Wigerup, C., Pakala, S. B., Natha, R. S., Gururaj, A. E., et al. (2010). Acetylation-dependent oncogenic activity of metastasis-associated protein 1 co-regulator. EMBO Reports, 11(9), 691–697. doi:10.1038/embor.2010.99.PubMedCentralPubMedCrossRef

42.

Pakala, S. B., Singh, K., Reddy, S. D., Ohshiro, K., Li, D. Q., Mishra, L., et al. (2011). TGF-beta1 signaling targets metastasis-associated protein 1, a new effector in epithelial cells. Oncogene, 30(19), 2230–2241. doi:10.1038/onc.2010.608.PubMedCentralPubMedCrossRef

43.

Mazumdar, A., Wang, R. A., Mishra, S. K., Adam, L., Bagheri-Yarmand, R., Mandal, M., et al. (2001). Transcriptional repression of oestrogen receptor by metastasis-associated protein 1 corepressor. Nature Cell Biology, 3(1), 30–37.PubMedCrossRef

44.

Luo, J. Y., Su, F., Chen, D. L., Shiloh, A., & Gu, W. (2000). Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature, 408(6810), 377–381.PubMedCrossRef

45.

Yoo, Y. G., Kong, G., & Lee, M. O. (2006). Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1 alpha protein by recruiting histone deacetylase 1. EMBO Journal, 25(6), 1231–1241. doi:10.1038/sj.emboj.7601025.PubMedCentralPubMedCrossRef

46.

Gururaj, A. E., Singh, R. R., Rayala, S. K., Holm, C., den Hollander, P., Zhang, H., et al. (2006). MTA1, a transcriptional activator of breast cancer amplified sequence 3. Proceedings of the National Academy of Sciences of the United States of America, 103(17), 6670–6675. doi:10.1073/pnas.0601989103.PubMedCentralPubMedCrossRef

47.

Balasenthil, S., Gururaj, A. E., Talukder, A. H., Bagheri-Yarmand, R., Arrington, T., Haas, B. J., et al. (2007). Identification of Pax5 as a target of MTA1 in B-cell lymphomas. Cancer Research, 67(15), 7132–7138. doi:10.1158/0008-5472.Can-07-0750.PubMedCrossRef

48.

Cobaleda, C., Schebesta, A., Delogu, A., & Busslinger, M. (2007). Pax5: the guardian of B cell identity and function. Nature Immunology, 8(5), 463–470. doi:10.1038/ni1454.PubMedCrossRef

49.

Pakala, S. B., Bui-Nguyen, T. M., Reddy, S. D., Li, D. Q., Peng, S., Rayala, S. K., et al. (2010). Regulation of NF-kappaB circuitry by a component of the nucleosome remodeling and deacetylase complex controls inflammatory response homeostasis. Journal of Biological Chemistry, 285(31), 23590–23597. doi:10.1074/jbc.M110.139469.PubMedCentralPubMedCrossRef

50.

Pakala, S. B., Reddy, S. D., Bui-Nguyen, T. M., Rangparia, S. S., Bommana, A., & Kumar, R. (2010). MTA1 coregulator regulates LPS response via MyD88-dependent signaling. Journal of Biological Chemistry, 285(43), 32787–32792. doi:10.1074/jbc.M110.151340.PubMedCentralPubMedCrossRef

51.

Ghanta, K. S., Pakala, S. B., Reddy, S. D., Li, D. Q., Nair, S. S., & Kumar, R. (2011). MTA1 coregulation of transglutaminase 2 expression and function during inflammatory response. Journal of Biological Chemistry, 286(9), 7132–7138. doi:10.1074/jbc.M110.199273.PubMedCentralPubMedCrossRef

52.

Coussens, L. M., & Werb, Z. (2002). Inflammation and cancer. Nature, 420(6917), 860–867. doi:10.1038/nature01322.PubMedCentralPubMedCrossRef

53.

Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related inflammation. Nature, 454(7203), 436–444. doi:10.1038/nature07205.PubMedCrossRef

54.

Divijendra, S., Reddy, N., Pakala, S. B., Ohshiro, K., Rayala, S. K., & Kumar, R. (2009). MicroRNA-661, a c/EBP alpha target, inhibits metastatic tumor antigen 1 and regulates its functions. Cancer Research, 69(14), 5639–5642. doi:10.1158/0008-5472.can-09-0898.CrossRef

55.

Bui-Nguyen, T. M., Pakala, S. B., Sirigiri, D. R., Martin, E., Murad, F., & Kumar, R. (2010). Stimulation of inducible nitric oxide by hepatitis B virus transactivator protein HBx requires MTA1 coregulator. Journal of Biological Chemistry, 285(10), 6980–6986. doi:10.1074/jbc.M109.065987.PubMedCentralPubMedCrossRef

56.

Li, Y., VandenBoom, T. G., II, Wang, Z., Kong, D., Ali, S., Philip, P. A., et al. (2010). miR-146a suppresses invasion of pancreatic cancer cells. Cancer Research, 70(4), 1486–1495. doi:10.1158/0008-5472.can-09-2792.PubMedCentralPubMedCrossRef

57.

Kaller, M., Liffers, S.-T., Oeljeklaus, S., Kuhlmann, K., Roeh, S., Hoffmann, R., et al. (2011). Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. Molecular & Cellular Proteomics, 10(8), doi:10.1074/mcp.M111.010462.

58.

Zhou, H., Xu, X., Xun, Q., Yu, D., Ling, J., Guo, F., et al. (2012). microRNA-30c negatively regulates endometrial cancer cells by targeting metastasis-associated gene-1. Oncology Reports, 27(3), 807–812. doi:10.3892/or.2011.1574.PubMed

59.

Xia, Y., Chen, Q., Zhong, Z., Xu, C., Wu, C., Liu, B., et al. (2013). Down-regulation of miR-30c promotes the invasion of non-small cell lung cancer by targeting MTA1. Cellular Physiology and Biochemistry, 32(2), 476– 485. doi:10.1159/000354452.

60.

Chu, H., Chen, X., Wang, H., Du, Y., Wang, Y., Zang, W., et al. (2014). MiR-495 regulates proliferation and migration in NSCLC by targeting MTA3. Tumor Biology, 35(4), 3487–3494. doi:10.1007/s13277-013-1460-1.PubMedCrossRef

61.

Baek, D., Villen, J., Shin, C., Camargo, F. D., Gygi, S. P., & Bartel, D. P. (2008). The impact of microRNAs on protein output. Nature, 455(7209), 64–71. doi:10.1038/nature07242.PubMedCentralPubMedCrossRef

62.

Selbach, M., Schwanhausser, B., Thierfelder, N., Fang, Z., Khanin, R., & Rajewsky, N. (2008). Widespread changes in protein synthesis induced by microRNAs. Nature, 455(7209), 58–63. doi:10.1038/nature07228.PubMedCrossRef

63.

He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., et al. (2007). A microRNA component of the p53 tumour suppressor network. Nature, 447(7148), 1130–1134. doi:10.1038/nature05939.PubMedCrossRef

64.

Zhu, X., Zhang, X., Wang, H., Song, Q., Zhang, G., Yang, L., et al. (2012). MTA1 gene silencing inhibits invasion and alters the microRNA expression profile of human lung cancer cells. Oncology Reports, 28(1), 218–224. doi:10.3892/or.2012.1770.PubMed

65.

Li, Y., Chao, Y., Fang, Y., Wang, J., Wang, M., Zhang, H., et al. (2013). MTA1 promotes the invasion and migration of non-small cell lung cancer cells by downregulating miR-125b. Journal of Experimental & Clinical Cancer Research, 32, doi:10.1186/1756-9966-32-33.

66.

Kumar, R., Wang, R. A., Mazumdar, A., Talukder, A. H., Mandal, M., Yang, Z. B., et al. (2002). A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature, 418(6898), 654–657. doi:10.1038/nature00889.PubMedCrossRef

Titel: Post-transcriptional regulation of MTA family by microRNAs in the context of cancer
verfasst von: Yun Zhang
Xiao-Fan Wang
Publikationsdatum: 01.12.2014
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 4/2014
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-014-9526-0

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Post-transcriptional regulation of MTA family by microRNAs in the context of cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Physiological functions of MTA family of proteins

Role of MTA1 in cancer progression and metastasis

Properties and clinical relevance of MTA1 protein in human cancer

Biography—Rakesh Kumar, Ph.D.

Identification and characterization of metastasis-associated gene/protein 1 (MTA1)

Subcellular localization of MTA proteins in normal and cancer cells

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie